Oncology

The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
HER2 is a membrane-bound tyrosine kinase that when amplified contributes significantly to a tumor’s ability to proliferate and survive.
[[thumbnail_alt_text]]
Patients with ulcerative colitis have an increased risk of developing colorectal cancer (CRC), are diagnosed with less advanced CRC, and are at increased risk of death from CRC.
[[thumbnail_alt_text]]
Guidelines indicate that there are a number of treatment options for head and neck cancers.
[[thumbnail_alt_text]]
Patients diagnosed with Crohn disease and colorectal cancer (CRC) have a higher rate of mortality than patients without Crohn disease who are also diagnosed with CRC.
[[thumbnail_alt_text]]
In a Directions in Oncology PharmacyTM Peer Exchange series, experts explained the right time to use bevacizumab, either as a front-line therapy or at the time of disease progression.
 
[[thumbnail_alt_text]]
In a Directions in Oncology Pharmacy Peer Exchange series, experts discuss the PRIMA trial and the rationale for using PARP inhibitors.
[[thumbnail_alt_text]]
Bhavesh Shah, RPh, BCOP, and Katherine Lin, PharmD, BCOP, provide input on individualizing early treatment for chemotherapy-induced nausea and vomiting.
[[thumbnail_alt_text]]
Enfortumab vedotin-ejfv in combination with the anti-PD1-therapy pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.
[[thumbnail_alt_text]]
The FDA has accepted Genentech’s supplemental biologics license application (sBLA) and granted priority review for atezolizumab (Tecentriq) as a first-line monotherapy for some patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC).
[[thumbnail_alt_text]]
In the pivotal phase 3 KEYNOTE-355 study, pembrolizumab (Keytruda, Merck) combined with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed programmed death-ligand 1 (PD-L1).
 
[[thumbnail_alt_text]]
The DKFZ discovered traces of a total of 23 different virus types in 356 patients with cancer. The most common drivers of tumor initiation and growth were found, including the genome of Epstein-Barr viruses (EBV) and hepatitis B virus (HBV).
[[thumbnail_alt_text]]
Physicians treating patients with platinum-sensitive ovarian cancer can choose from a range of therapies, including doublet chemotherapy with or without bevacizumab (Avastin) and PARP inhibitors.